Chairmen
Siegfried Kasper (Chairman)
For the period 2012 to 2016, he was elected to the Executive Committee of the International College of Neuropsychopharmacology (CINP). He is also Chair of the World Psychiatric Association (WPA) Section of Pharmacopsychiatry. Kasper is the editor of the World Journal of Biological Psychiatry, the International Journal of Psychiatry in Clinical Practice, Field Editor for the International Journal of Neuropsychopharmacology, Section Editor for Expert Opinion on Pharmacotherapy and Field Editor of Psychiatry, Journal of Neurology, Neurosurgery, and Psychiatry. |
Stuart. A Montgomery (Co-Chairman)
He has been a member of the Committee on Safety of Medicines. He is Editor of International Clinical Psychopharmacology and was co-Editor of European Neuropsychopharmacology for twenty years. Early in his career he developed the widely used MADRS and he is well known for his research into the treatment of schizophrenia, bipolar disorder, depression and the anxiety disorders. Download COI Disclosure |
Siegfried Kasper was born on December 15th, 1950 in Salzburg. He is the Chairman of the Department of Psychiatry and Psychotherapy of the Medical University of Vienna, Austria.
Stuart Montgomery was Professor of Psychiatry at Imperial College, University of London until his retirement in 1996 when the title of Emeritus Professor of Psychiatry was conferred. He was President of the European College of Neuropsychopharmacology (ECNP) from 1992 to 1995 and President of the British Association of Psychopharmacology from 1990 to 1992.
Speakers
David Baldwin |
||
|
He became Head of the Mental Health Group in 2008 and was awarded a Personal Chair in 2010. Professor Baldwin leads a group that aims to improve clinical outcomes in patients with mood and anxiety disorders. He leads the Anxiety Disorders Research Network, an international multi-centre independent collaborative cross-disciplinary research grouping and is an Honorary Consultant Psychiatrist in Southern Health NHS Foundation Trust, where he leads the tertiary referral specialist service for patients with mood and anxiety disorders. Download COI Disclosure |
||
Professor Baldwin trained in medicine at Charing Cross Hospital Medical School, London and then in psychiatry at St Mary’s Hospital Medical School and the Maudsley Hospital, London.
Borwin Bandelow |
||
|
Bandelow is editor of the scientific journal German Journal of Psychiatry and president of the German Society for Anxiety Research. Since 2007, Bandelow is a member of the Göttingen doctors band “Hot Docs”. Download COI Disclosure |
||
He is Professor for Psychiatry and Psychotherapy and Deputy Director of the Department for Psychiatry and Psychotherapy at the University of Göttingen and an international expert for anxiety disorders. He has authored over 300 scientific publications.
Timothy Dinan |
||
|
Prior to that he was a Senior Lecturer in Psychiatry at Trinity College Dublin. He has worked in research laboratories on both sides of the Atlantic and has a PhD in Pharmacology from the University of London. He is a Fellow of the Royal Colleges of Physicians and Psychiatrists and a Fellow of the American College of Physicians. He has published over 400 papers and numerous books on the pharmacology and neurobiology of affective disorders. His primary research focus is on immune and endocrine aspects of depression and irritable bowel syndrome. Download COI Disclosure |
||
He was previously Chair of Clinical Neurosciences and Professor of Psychological Medicine at St. Bartholomew’s Hospital, London.
Joseph F Hulihan |
||
|
Dr. Hulihan completed neurology residency at Drexel University in Philadelphia and a clinical neurophysiology fellowship at Mayo Clinic. Prior to joining Johnson & Johnson, he held the position of Associate Professor of Neurology and Director of the EEG Laboratory and Clinical Neurophysiology fellowship at Temple University. . Dr. Hulihan serves as on the boards of the American Society of Experimental Therapeutics (ASENT) and has previously been a board member and chair of the Professional Advisory Board for the Philadelphia affiliate of the Epilepsy Foundation. He is currently completing study towards a Master’s degree in health policy at Thomas Jefferson University in Philadelphia, focusing on mental health policy, particularly mental health / criminal justice interactions. COI Disclosure soon available |
||
Dr. Joe Hulihan is Global Medical Affairs Leader for Neuroscience at Janssen Global Services, a Johnson & Johnson company. His primary therapeutic area focus is currently in mood disorders. Prior to this, Dr. Hulihan directed medical affairs activities in schizophrenia, ADHD and pain medicine as Vice President of Medical Affairs for Central Nervous System Diseases at Janssen Pharmaceuticals in the U.S., a position he held from 2005 to mid-2013. He joined J&J in 1999 as Director of CNS Research at Ortho-McNeil Pharmaceutical, and since then has held positions of increasing responsibility in medical and scientific affairs for neurology and psychiatry.
Stefano Pallanti |
||
|
He is a Fellow Member and the Scientific Board of ECNP ( European College of Neuropsychopharmacology) and serves in its Educational Committee. He is the Advisory Council of the International Center for Autism Research and Education (Icare4autism, New York) and the International Advisory Board of the American Psychiatric Association for the Diagnostic and Statistical Manual of Mental Disorders, for its Fourth Edition (DSM-IV) and the Obsessive Compulsive Disorder Spectrum Workgroup for the DSM-V. He is a member of the board of directors of the International College for Obsessive-Compulsive Syndromes (ICOCS) and an Associate Director of the European Certificate, International Master Course in Affective Neuroscience, Universities of Maastricht, Florence, Bristol and Tel Aviv. Since May 2013 he serves as a member of board of directors for Clinical TMS Society. His current collaborative research projects are in the areas of treatment-resistant OCD, PANDAS, Anxiety in Psychosis, Anxiety Disorder in pregnancy, the puerperium and postpartum, and the ADHD – OCD spectrum. He is particularly interested in rTMS and Neuromodulation treatments. He is a member of the Editorial Board of the American Journal of Psychiatry and of the CNS Spectrums, where he is also a columnist and International Editor of American Psychiatric Publishing Inc. Download COI Disclosure |
||
Stefano Pallanti is Professor of Psychiatry at the University of Florence in Italy where he has been Head and Director of the Clinical Psychology and Consultation Psychiatry Unit since 2009. He is Visiting Professor at Albert Einstein College of Medicine, and Adjunct Associate Professor at Icahn School of Medicine at Mount Sinai, where he served as the Founder and Director of the Center of Excellence for OCD, Impulsive and Behavioural Addiction. He was a Full Professor at the University of California Davis in 2013 – 2014.
Zoltan Rihmer |
||
|
From 2007 he is professor of psychiatry at the Department of Psychiatry and Psychotherapy, and scientific director at the Department of Clinical and Theoretical Mental Helath, Semmelweis University, Faculty of Medicine, Budapest. His special interest is the clinical and biological aspects of mood and anxiety disorders, with particular regards to prediction of treatment response and prevention of suicide. Download COI Disclosure |
||
Since then he has been working at the National Institute for Psychiatry and Neurology, Budapest, Hungary.
Alessandro Serretti |
||
|
1996 – Specialization in Psychiatry (mark 70/70 with honors) Milan University. 1997-2000 – Registrar, Psychiatry Department, San Raffaele Scientific Institute, Milan, Italy. 2000-2006 – Director of the Unit of Genetics in Mood Disorders, Psychiatry Department, San Raffaele Scientific Institute, Milan, Italy. 2001-2008 – Temporary Associate professor at Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy. 2006-2011 – Aggregate professor, tenured, Psychiatry Department, Bologna University, Bologna, Italy. 2011-present – Associate professor, tenured, Psychiatry Department, Bologna University, Bologna, Italy. Reviewers for over 100 international journals, of which 12 as member of the editorial board and 3 as associate editor (Clinical Neuropsychiatry, Current Medicinal Cheminstry, Journal of Alzheimer Disease). Reviewer for 35 international funding agencies including European Community. Coordinator of a research unit active in genetic and clinical studies of major psychoses is author of more than 400 peer reviewed international papers in the field of Mood disorders, Schizophrenia, Genetics of Major Psychoses, Therapy and Psychopathology. 15 book chapters, 450 abstracts at meetings of which more than 100 as invited speaker or chairman. H-Index=50. More than 10 international collaborations. Download COI Disclosure |
||
1991 – Degree in Medicine (mark 110/110 with honors), Catholic University, Rome, Italy.
Torgny Svensson |
||
|
He received his M.D./ Ph.D. degrees from the University of Gothenburg, Sweden, and subsequently spent several years in the US, working both at Yale University Medical School, Depts. of Pharmacology and Psychiatry, and at The Salk Institute, La Jolla, CA. His major scientific contributions concern the regulation and function of brain monoamine systems, the mode of action of antidepressant and antipsychotic drugs and various augmentation strategies, as well as the neurobiological basis of nicotine dependence and its treatment. Download COI Disclosure |
||
Torgny Svensson is Professor of Pharmacology since 1983 as well as a member of the Nobel Assembly at the Karolinska Institute in Stockholm, Sweden.
Eduard Vieta |
||
|
His research focuses on the neurobiology and treatment of bipolar disorder. He has published over 500 publications and is currently the most cited scientist in the field of bipolar disorders for the past 5 years. He has been awarded with the Mogens Schou Award, the Colvin Price, the Spanish Society of Psychiatry strategic research award, the Barcelona best doctors’award and the CINP Clinical neuroscience award. He is the current treasurer of the European College of Neuropsychopharmacology (ECNP). Download COI Disclosure |
||
Eduard Vieta is Professor of Psychiatry and the Chair of the Department of Psychiatry and Psychology of the Hospital Clinic at the University of Barcelona, Spain.
Allan Young |
||
|
London, United Kingdom (UK). He has held academic appointments at Oxford University; Newcastle University (latterly holding the Chair of General Psychiatry at Newcastle), University of British Columbia in Vancouver, Canada, where he held the Leading Edge Endowment Fund Endowed Chair in Research in the Department of Psychiatry and was also the Director of the Institute of Mental Health and Imperial College London, where he held the Chair of Psychiatry and was Director of the Centre for Mental Health. Professor Young’s research interests focus on the cause and treatments for severe psychiatric illnesses, particularly mood disorders. He has received research grant funding from the UK Medical Research Council, the Wellcome Trust, the Stanley Medical Research Institute, the Canadian Institutes for Heath Research (CIHR), the National Institutes of Health (USA), and numerous other funding agencies. He has published over 300 peer-reviewed publications and a number of books about psychopharmacology and affective disorders including Bipolar Disorders: Basic Mechanisms and Therapeutic Implications (2nd Ed) with J.C. Soares, and Practical Management of Bipolar Disorder with I.N. Ferrier and E. Michalak (Cambridge University Press, 2010). Download COI Disclosure |
||
Professor Allan Young holds the Chair of Mood Disorders and is Director of the Centre for Affective Disorders in the Department of Psychological Medicine in the Institute of Psychiatry at King’s College